Paper · 19008097

What is triple-negative breast cancer?

Irvin WJ and 1 other. Eur J Cancer, 2008. Cited by 251 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. What is triple-negative breast cancer? Papers, record 19008097. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19008097

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: What is triple-negative breast cancer?; PubMed
Journal: Eur J Cancer; PubMed
Year: 2008; PubMed
Publication types: Journal Article, Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/19008097/; PubMed
DOI: https://doi.org/10.1016/j.ejca.2008.09.034; PubMed
The journal: https://conductscience.org/library/journal-index/9005373; PubMed
Citations, by iCite: 251; iCite
Relative citation ratio, by iCite: 5.54; iCite
Revised in PubMed: 2026-01-28; PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Irvin WJ Jr	William J
2	Carey LA	Lisa A

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Biomarkers, Tumor	Major topic
Breast Neoplasms	Major topic
Antineoplastic Agents
Female
Humans
Prognosis
Erb-b2 Receptor Tyrosine Kinases
Receptors, Estrogen
Receptors, Progesterone
Risk Factors
Terminology as Topic

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by147

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 251 citations.

PMID	Title	Journal	Year	In Papers	Source
42,434,841	Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer.	Adv Healthc Mater	2026	https://conductscience.org/library/papers/42434841	PubMed
41,644,793	WGCNA-derived lncRNA MAP3K4-AS1 regulates apoptosis and cell cycle in TNBC MDA-MB-231 cells validated by siRNA knockdown.	Discov Oncol	2026	https://conductscience.org/library/papers/41644793	PubMed
41,565,619	Positive feedback regulation between USP8 and Hippo/YAP axis drives triple-negative breast cancer progression.	Cell Death Dis	2026	https://conductscience.org/library/papers/41565619	PubMed
41,476,708	The impact of the conjugation manner of targeting agent and tandem cell-penetrating peptide on the efficacy of mitomycin C liposomes in treating triple-negative breast tumors.	Int J Pharm X	2025	https://conductscience.org/library/papers/41476708	PubMed
41,261,289	Static magnetic field and alternating magnetic field cytotoxic effects on triple negative breast cancer cell line (MDA-MB-231).	Med Oncol	2025	https://conductscience.org/library/papers/41261289	PubMed
41,226,649	Combinative Treatment of the PARP Inhibitor Olaparib and Antimetastasis Ruthenium(II)-Arene Compound RAPTA-T for Triple-Negative BRCA1 Wild-Type Breast Cancer Cells.	Int J Mol Sci	2025	https://conductscience.org/library/papers/41226649	PubMed
41,114,181	Crocetin Impairs the Cytochrome P450 Epoxygenase Pathway toward Potentiating the Therapeutic Efficacy of Paclitaxel in Metastatic Breast Cancer.	ACS Omega	2025	https://conductscience.org/library/papers/41114181	PubMed
40,965,337	Fucosylated N-Glycan Landscape of Triple-Negative Breast Cancer.	Mol Cancer Res	2025	https://conductscience.org/library/papers/40965337	PubMed
40,730,890	Exploring the therapeutic role of carnosol in cancer: from molecular insights to clinical promise.	Med Oncol	2025	https://conductscience.org/library/papers/40730890	PubMed
40,426,927	Clinical Significance of Tumor Grade in Triple-Negative Breast Cancer: A Retrospective Cohort Analysis.	Biomedicines	2025	https://conductscience.org/library/papers/40426927	PubMed

1 to 10 of 147

See all 147 cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
BRCA1	672	PubTator's text mining	https://conductscience.org/library/genes/672	NCBI Gene
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
EREG	2,069	PubTator's text mining	https://conductscience.org/library/genes/2069	NCBI Gene
PGR	5,241	PubTator's text mining	https://conductscience.org/library/genes/5241	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19008097

GET https://conductscience.org/api/papers/v1/19008097/cited_by?page=2

API reference For AI assistants